Tirzepatide GLP-1 Injection - Medical Weight Loss

Dual-Action Weight Loss Support with Powerful Results

Tirzepatide is a next-generation, once-weekly injectable medication designed to help manage obesity and improve metabolic health. As a dual GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist, tirzepatide mimics the action of key gut hormones that regulate blood sugar, appetite, and digestion. This unique mechanism not only enhances insulin secretion and slows down how quickly food leaves the stomach, but also promotes a lasting feeling of fullness—making it easier to reduce calorie intake and maintain consistent weight loss.

Unlike older GLP-1 medications, tirzepatide’s dual hormone action provides more robust effects on appetite and metabolism. Clinical studies have shown that many patients lose up to 20% of their body weight with continued use, making it one of the most effective medical weight loss options currently available.

Tirzepatide is administered as a once-weekly subcutaneous injection, with a gradual dose escalation schedule to improve tolerance and reduce gastrointestinal side effects. Treatment typically begins at 2.5 mg per week (for tolerability), with increases in 2.5 mg steps every 4 weeks until the optimal dose is reached—up to a maximum of 15 mg weekly. Most patients settle at the dose that provides effective weight loss with minimal side effects.

The most common side effects are mild and digestive in nature—such as nausea, constipation, diarrhea, or abdominal discomfort—especially in the early weeks. These symptoms typically improve as the body adjusts. Eating smaller meals and avoiding rich or greasy foods can help minimize these effects.

Tirzepatide offers a powerful combination of weight loss, improved glycemic control, and reduced appetite—all with the convenience of once-weekly dosing. With consistent use and support, it can be a transformative tool for long-term weight and health management.